BudesonideGlycopyrroniumFormoterolQualityChecker
Budesonide/Glycopyrronium/Formoterol Quality Checker
ℹ️ Utility checks critical parameters of triple combination (ICS/LAMA/LABA):
• Budesonide Content: 144–198 mcg/dose
• Glycopyrronium Content: 7.2–10.8 mcg/dose
• Formoterol Content: 3.6–5.4 mcg/dose
• Fine Particle Fraction (FPF): ≥15%
• Dose Uniformity: deviation ≤15%
• Moisture Content: ≤1.0%
• Impurities: ≤1.5%
• Valve Leak Rate: ≤0.5 mL/min
• Actuator Force: 15–25 N
⚠️ CRITICAL: Low fine particle fraction reduces delivery of all three components to the lungs.
Violation of dosage of any component reduces COPD/asthma therapy efficacy.
Usage:
BudesonideGlycopyrroniumFormoterolQualityChecker.exe → demo mode
BudesonideGlycopyrroniumFormoterolQualityChecker.exe input.csv output.json → evaluate data
Input format:
BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce
Example:
BGF-2026-001,160.0,9.0,4.5,20.5,7.0,0.4,0.7,0.2,19.0
— WHY IS THIS NEEDED?
Triple combination of budesonide (ICS), glycopyrronium (LAMA), and formoterol (LABA) is used for treating severe asthma and COPD:
• Budesonide — corticosteroid, reduces inflammation
• Glycopyrronium — long-acting anticholinergic, bronchodilator
• Formoterol — long-acting beta-agonist, smooth muscle relaxant
• Combination of three mechanisms provides maximum symptom control
• Inhalation form requires strict control of aerodynamic properties
⚠️ CRITICAL:
• Component content must be within a narrow range for therapeutic effect
• Fine Particle Fraction (FPF) determines the fraction of drug reaching alveoli
• Dose uniformity is critical for patient safety with each inhalation
• Moisture affects powder flowability and valve operation
• System tightness prevents drug loss and contamination
Key features:
• Comprehensive check of three active substances with different mechanisms of action
• Control of aerodynamic parameters (FPF)
• Assessment of mechanical device characteristics (valve, actuator)
• Stability check of composition (moisture, impurities)
Critical parameters:
• Budesonide Assay: 144–198 mcg/dose
• Glycopyrronium Assay: 7.2–10.8 mcg/dose
• Formoterol Assay: 3.6–5.4 mcg/dose
• Fine Particle Fraction: ≥15%
• Dose Uniformity Deviation: ≤15%
• Moisture Content: ≤1.0%
• Total Impurities: ≤1.5%
• Valve Leak Rate: ≤0.5 mL/min
• Actuator Force: 15–25 N
💡 Usage tips:
1. Content determined by HPLC after extraction from inhaler
2. Fine Particle Fraction measured using cascade impactor (USP <601>)
3. Dose uniformity tested on a series of inhalations
4. Moisture controlled by Karl Fischer method
5. Tightness checked on specialized leak testers
⚠️ Note: Triple inhalers represent the pinnacle of complexity in respiratory drug development. Balance between three different molecules, their physicochemical properties, and particle aerodynamics requires precision control. Any deviation in dosage or particle size can significantly reduce clinical efficacy of therapy.
input.csv
BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce BGF-2026-001,160.0,9.0,4.5,20.5,7.0,0.4,0.7,0.2,19.0 BGF-2026-002,155.0,8.5,4.2,18.0,8.5,0.5,0.9,0.3,18.5
BudesonideGlycopyrroniumFormoterolQualityChecker — Documentation
input.csv and *.description.txt. Package folder: Global/API coverage extension.Utility description
Budesonide/Glycopyrronium/Formoterol Quality Checker — Triple Inhaler (ICS/LAMA/LABA) Quality Control
ℹ️ Utility checks critical parameters of triple combination (ICS/LAMA/LABA):
• Budesonide Content: 144–198 mcg/dose
• Glycopyrronium Content: 7.2–10.8 mcg/dose
• Formoterol Content: 3.6–5.4 mcg/dose
• Fine Particle Fraction (FPF): ≥15%
• Dose Uniformity: deviation ≤15%
• Moisture Content: ≤1.0%
• Impurities: ≤1.5%
• Valve Leak Rate: ≤0.5 mL/min
• Actuator Force: 15–25 N
⚠️ CRITICAL: Low fine particle fraction reduces delivery of all three components to the lungs.
Violation of dosage of any component reduces COPD/asthma therapy efficacy.
Usage:
BudesonideGlycopyrroniumFormoterolQualityChecker.exe → demo mode
BudesonideGlycopyrroniumFormoterolQualityChecker.exe input.csv output.json → evaluate data
Input format:
BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce
Example:
BGF-2026-001,160.0,9.0,4.5,20.5,7.0,0.4,0.7,0.2,19.0
— WHY IS THIS NEEDED?
Triple combination of budesonide (ICS), glycopyrronium (LAMA), and formoterol (LABA) is used for treating severe asthma and COPD:
• Budesonide — corticosteroid, reduces inflammation
• Glycopyrronium — long-acting anticholinergic, bronchodilator
• Formoterol — long-acting beta-agonist, smooth muscle relaxant
• Combination of three mechanisms provides maximum symptom control
• Inhalation form requires strict control of aerodynamic properties
⚠️ CRITICAL:
• Component content must be within a narrow range for therapeutic effect
• Fine Particle Fraction (FPF) determines the fraction of drug reaching alveoli
• Dose uniformity is critical for patient safety with each inhalation
• Moisture affects powder flowability and valve operation
• System tightness prevents drug loss and contamination
Key features:
• Comprehensive check of three active substances with different mechanisms of action
• Control of aerodynamic parameters (FPF)
• Assessment of mechanical device characteristics (valve, actuator)
• Stability check of composition (moisture, impurities)
Critical parameters:
• Budesonide Assay: 144–198 mcg/dose
• Glycopyrronium Assay: 7.2–10.8 mcg/dose
• Formoterol Assay: 3.6–5.4 mcg/dose
• Fine Particle Fraction: ≥15%
• Dose Uniformity Deviation: ≤15%
• Moisture Content: ≤1.0%
• Total Impurities: ≤1.5%
• Valve Leak Rate: ≤0.5 mL/min
• Actuator Force: 15–25 N
💡 Usage tips:
1. Content determined by HPLC after extraction from inhaler
2. Fine Particle Fraction measured using cascade impactor (USP <601>)
3. Dose uniformity tested on a series of inhalations
4. Moisture controlled by Karl Fischer method
5. Tightness checked on specialized leak testers
⚠️ Note: Triple inhalers represent the pinnacle of complexity in respiratory drug development. Balance between three different molecules, their physicochemical properties, and particle aerodynamics requires precision control. Any deviation in dosage or particle size can significantly reduce clinical efficacy of therapy.URS & FS — User Requirements and Functional Specification
This document describes the controlled interface and behaviour of BudesonideGlycopyrroniumFormoterolQualityChecker for Budesonide/Glycopyrronium/Formoterol Quality Checker.
Portal packages
Global/API coverage extension, LabEx QC laboratory utilities, Lumex QC instrument utilities, Medical Gases / inhaler-adjacent QC Suite, World API/FDC extension
AsthmaCOPDCSV→JSONFDCInhalerMissingAPIQCRespiratoryURS & FSP1Domain limits and critical parameters
- ℹ️ Utility checks critical parameters of triple combination (ICS/LAMA/LABA):
- • Budesonide Content: 144–198 mcg/dose
- • Glycopyrronium Content: 7.2–10.8 mcg/dose
- • Formoterol Content: 3.6–5.4 mcg/dose
- • Fine Particle Fraction (FPF): ≥15%
- • Dose Uniformity: deviation ≤15%
- • Moisture Content: ≤1.0%
- • Impurities: ≤1.5%
- • Valve Leak Rate: ≤0.5 mL/min
- ⚠️ CRITICAL: Low fine particle fraction reduces delivery of all three components to the lungs.
- BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce
- ⚠️ CRITICAL:
- • Component content must be within a narrow range for therapeutic effect
- • Dose uniformity is critical for patient safety with each inhalation
- • Stability check of composition (moisture, impurities)
- Critical parameters:
- • Budesonide Assay: 144–198 mcg/dose
- • Glycopyrronium Assay: 7.2–10.8 mcg/dose
URS — User Requirements Specification
| ID | Requirement | Criticality | Acceptance criterion |
|---|---|---|---|
| URS-001 | The utility shall accept an input.csv file for Budesonide/Glycopyrronium/Formoterol Quality Checker with headers defined in the data contract. | High | The file is processed without manual header editing. |
| URS-002 | The utility shall perform deterministic QC evaluation without machine learning and without probabilistic conformance decisions. | High | Identical input data, rule version and configuration produce reproducible results. |
| URS-003 | The utility shall validate mandatory fields, data types, ranges, units and domain plausibility. | High | Schema, conversion and range errors are explicitly reported. |
| URS-004 | The utility shall apply domain limits and rules from the description, approved specification, registration dossier and local SOPs. | High | Each check has PASS/WARNING/FAIL and a clear message. |
| URS-005 | The utility shall generate output.json with machine-readable results, source values, warnings, failures and critical findings. | High | JSON is suitable for LIMS/ELN/MES integration and QA/QC review. |
| URS-006 | The utility shall preserve traceability between batch/sample, input file, applied rules and final status. | High | Output contains identifiers, checked parameters and audit metadata. |
| URS-007 | The documentation shall support IQ/OQ/PQ, CSV/CSA and review by internal QA or inspectors. | Medium | URS, FS, input/output contract and test scenarios are supplied with the utility. |
| URS-008 | The utility shall be used as a QC decision-support tool and not as a substitute for approved specifications and QA/QP release decision. | Medium | Documentation states change control and limit-verification expectations. |
input.csv contract
| # | Field | Type | Sample | Purpose |
|---|---|---|---|---|
| 1 | BatchNumber | string / controlled vocabulary | BGF-2026-001 | Batch or lot identifier used for traceability. |
| 2 | BudesonideAssay | decimal | 160.0 | Quantitative content/potency; critical release parameter. |
| 3 | GlycopyrroniumAssay | decimal | 9.0 | Quantitative content/potency; critical release parameter. |
| 4 | FormoterolAssay | decimal | 4.5 | Quantitative content/potency; critical release parameter. |
| 5 | FineParticleFraction | decimal | 20.5 | Size/particle attribute; physicochemical quality parameter. |
| 6 | DDUDeviation | decimal | 7.0 | Controlled input parameter for deterministic QC rules. |
| 7 | Moisture | decimal | 0.4 | Moisture/water parameter relevant to stability. |
| 8 | Impurities | decimal | 0.7 | Impurity/related-substance parameter; purity and degradation control. |
| 9 | ValveLeak | decimal | 0.2 | Controlled input parameter for deterministic QC rules. |
| 10 | ActuatorForce | decimal | 19.0 | Controlled input parameter for deterministic QC rules. |
BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce BGF-2026-001,160.0,9.0,4.5,20.5,7.0,0.4,0.7,0.2,19.0 BGF-2026-002,155.0,8.5,4.2,18.0,8.5,0.5,0.9,0.3,18.5
Input validation rules
| ID | Field | Rule | Criticality |
|---|---|---|---|
| VR-001 | BatchNumber | The field shall match an approved dictionary or accepted string representation. | High |
| VR-002 | BudesonideAssay | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-003 | GlycopyrroniumAssay | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-004 | FormoterolAssay | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-005 | FineParticleFraction | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-006 | DDUDeviation | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-007 | Moisture | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-008 | Impurities | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-009 | ValveLeak | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-010 | ActuatorForce | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
FS — Functional Specification
| ID | Function | Implementation |
|---|---|---|
| FS-001 | CLI execution | Support execution modes: demo mode without arguments and production mode input.csv output.json. |
| FS-002 | CSV import | Read input.csv in UTF-8/CSV-compatible format and validate header and expected columns. |
| FS-003 | Schema validation | Check mandatory fields, column count, unknown key fields and empty mandatory values. |
| FS-004 | Type conversion | Convert numeric, flag and text values; invalid format is recorded as a row-level error. |
| FS-005 | Domain rule engine | Apply rules for Budesonide/Glycopyrronium/Formoterol Quality Checker, including critical limits from the description and approved specification. |
| FS-006 | Status aggregation | Produce final status: FAIL for critical failure, WARNING for non-critical deviation, PASS for conformance. |
| FS-007 | JSON export | Write output.json with detailed checks, source values, warnings, failures and critical findings. |
| FS-008 | Audit support | Keep result structure suitable for review, deviation investigation and calculation reproduction. |
| FS-009 | Integration contract | Support the scenario LIMS/ELN/MES → input.csv → utility → output.json → portal/admin review. |
| FS-010 | Fallback mapping | If the combined utility is not deployed, use component checks: budesonide-quality-checker, glycopyrronium-quality-checker, formoterol-quality-checker plus generic Lumex/LabEx checks. |
| FS-011 | Error handling | Return explicit messages for missing file, empty CSV, invalid schema, output write failure and invalid format. |
Example output.json
{
"utilityId": "budesonide-glycopyrronium-formoterol-quality-checker",
"utilityFolder": "BudesonideGlycopyrroniumFormoterolQualityChecker",
"package": "Global/API coverage extension",
"overallStatus": "PASS|WARNING|FAIL",
"sourceFile": "input.csv",
"processedAtUtc": "2026-07-02T00:00:00Z",
"checks": [
{
"parameter": "BatchNumber",
"value": "BGF-2026-001",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-001"
},
{
"parameter": "BudesonideAssay",
"value": "160.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-002"
},
{
"parameter": "GlycopyrroniumAssay",
"value": "9.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-003"
},
{
"parameter": "FormoterolAssay",
"value": "4.5",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-004"
},
{
"parameter": "FineParticleFraction",
"value": "20.5",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-005"
},
{
"parameter": "DDUDeviation",
"value": "7.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-006"
},
{
"parameter": "Moisture",
"value": "0.4",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-007"
},
{
"parameter": "Impurities",
"value": "0.7",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-008"
},
{
"parameter": "ValveLeak",
"value": "0.2",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-009"
},
{
"parameter": "ActuatorForce",
"value": "19.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-010"
}
],
"criticalFindings": [],
"warnings": [],
"audit": {
"inputHash": "sha256:<calculated at runtime>",
"rulesVersion": "<utility executable version>",
"documentation": "BudesonideGlycopyrroniumFormoterolQualityChecker.documentation.html"
}
}
Traceability matrix
| URS | FS | Test | Evidence |
|---|---|---|---|
| URS-001 | FS-001, FS-002 | OQ-001 | Verify execution and import of valid input.csv. |
| URS-002 | FS-005, FS-006 | OQ-004 | Repeat the same dataset and compare output.json. |
| URS-003 | FS-003, FS-004, FS-011 | OQ-002, OQ-003 | Verify missing columns and invalid types. |
| URS-004 | FS-005, FS-006 | OQ-004, PQ-001 | Verify critical deviations on real/boundary data. |
| URS-005 | FS-007, FS-009 | OQ-005 | Verify JSON schema and downstream-system suitability. |
| URS-006 | FS-008 | OQ-006 | Verify identifiers and audit metadata. |
| URS-007 | FS-008, FS-011 | IQ-001, OQ-007 | Verify documentation completeness and control evidence. |
| URS-008 | FS-005, FS-008, FS-010 | PQ-002 | Verify review workflow and no replacement of QA decision. |
IQ/OQ/PQ test scenarios
| ID | Scenario | Expected result |
|---|---|---|
| IQ-001 | Verify executable, input.csv, documentation and checksum availability. | Delivery set is complete; version is recorded. |
| OQ-001 | Valid sample row from input.csv. | PASS or acceptable WARNING according to rules. |
| OQ-002 | Remove a mandatory CSV column. | Schema error or FAIL with missing-column reference. |
| OQ-003 | Place a non-numeric value into a numeric field. | Type-conversion error with row/field reference. |
| OQ-004 | Set a critical parameter outside the limit. | FAIL and critical finding. |
| OQ-005 | Verify output.json structure. | All mandatory sections are present and JSON is valid. |
| OQ-006 | Verify batch/sample traceability. | Input and result identifiers match. |
| OQ-007 | Verify fallback/decomposition for combined APIs. | Component checks are explicitly documented. |
| PQ-001 | Verify 3–5 real user batches/samples. | Result is confirmed by QC/QA review. |
| PQ-002 | Verify deviation workflow and manual QA decision. | Utility supports review but does not replace approved decision. |
QA/QC and change control
- Do not rename columns without updating validator, documentation and test set.
- Retain input.csv, output.json, executable version and checksum.
- Before production use, perform IQ/OQ/PQ or equivalent CSV/CSA verification.
- Critical limits shall be verified against the approved specification, registration dossier and local SOPs.
- For combination products, document whether the specialized FDC utility or fallback component checks were used.
- The utility provides structured QC decision support; final release decision remains with QA/QP and approved procedures.
Included in packages
Global API & Biosimilars QC Suite
Package for high-demand global APIs, generics and biosimilars, including fixed-dose combinations and biological products.
OpenMedical Gases QC Suite
Quality-control package for medical and pharmaceutical gases: oxygen, nitrogen, carbon dioxide, nitrous oxide, helium and mixtures.
OpenWorld API Extension QC Suite
Extended package for 130 additional high-demand APIs and biological products prepared as a market-coverage backlog.
Open